Watershed Bio’s Post

Discover how Watershed Bio and Violet Therapeutics collaborated to build a custom RABID-seq pipeline in our latest case study summary. And access the full study on our website: https://lnkd.in/eTW_g7PE #watershedbio #bioinformatics #dataanalytics

Did you hear that we recently acquired AbCheck s.r.o.? Learn more about the acquisition and how it boosts our Address, Navigate, Determine (AND)™ Platform and enhances our ability to generate multiple AND-Body™ Therapeutics in parallel: https://bit.ly/47AA18g #Biotechnology #Healthcare #DrugDiscovery #DrugDevelopment

Why not consider a different approach to your cell culture scaling? Watch the full video to learn more. https://lnkd.in/dSUXzfRe #biotech #biopharma #mabs #cellculture #bioprocessing

As the CMO of Legend Biotech, Mythili Koneru, MD, explains how she is approaching her role. Learn more about what her primary focuses are and her tips and insights on being a first time CMO in our interview with her below. Read the article here: https://lnkd.in/e8JepAtj #BioTech #CMO #ChiefMedicalOfficer

In an exclusive interview with Global Business Report (GBR), Subodh Deshmukh, CEO of Biologics and President of Development, along with Ramesh Subramanian, CCO of Aragen Life Sciences, share insights about the growth of biologics in the USA and key insights on why automation is important in the CDMO and CRO segments in the current scenario. Click on the link below to get complete insight into the current dynamics of the CDMO and CRO industry. #interview #cdmo #cro #drugdevelopment #biologics #usa #lifesciencesupdates #markettrends #exclusive

FibroBiologics is set to join the Russell 2000® Index effective July 1, 2024, according to a preliminary list of additions. This milestone reflects our growth and commitment to developing novel therapeutics using fibroblasts. Joining the #Russell2000 marks a significant step in increasing our visibility in the investment community and enhancing shareholder value. For more: https://bit.ly/4cHC6ST #Biotechnology #InvestmentGrowth

Dimerix Limited (ASX:DXB, OTC:SBMJF) CEO and managing director Dr Nina Webster is in the Proactive studio following the 18th annual Bioshares Biotech Summit in Perth. Dimerix is is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using its innovative receptor technology to identify and develop drugs in areas with an unmet need. Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment (DMX-200) that may transform the lives of patients with #InflammatoryDiseases, such as kidney or lung diseases. Dimerix encourages collaboration and is well positioned to discuss partnering and product development. Watch at #Proactive #ProactiveInvestors #KidneyDisease #LungDisease #Biotech #Biopharmaceutcials Elisha Newell https://lnkd.in/eMT7kHqg

Earlier today, we shared a strategic update where we discussed progress towards our 2024 goals, including achievement of establishing in vivo preclinical proof of concept. Learn more: https://bit.ly/3YyS3GL #geneediting #biotechnology  

Informative webinar alert! Dive deep into the world of bioanalytical techniques and technologies used for today’s complex therapeutics. Hear from experts on how to optimize therapy strategies and tackle regulatory hurdles. Be part of the future—register now! https://bit.ly/4euih21 #Webinar #DrugDevelopment #Innovation #Pharma #BioTech #bioanalytical #bioanalyticalmethods #massspectrometry #massspec #chromatography #research #bioanalysis #lcms #hrms #largemolecule #PHRMA #AAPS #biotechnology #bostonbiotech #seattlebiotech #sanfranciscobiotech #sandiegobiotech #genomics #flowcytometry

A critical issue for all emerging biopharmaceutical companies is their valuation- and how clinical trial results from their assets impact on that. This #IQVIA webinar discusses original research by IQVIA statistically analysing the link between valuation changes for biotech companies and types of clinical trials outcomes announcements. Recommended for a statistically robust, quantitative approach to a key #Biotech business issue.